Obesity
Efficacy of Injectable Weight Loss Medication in Persons with Type 2 Diabetes
Intro: This study will compare injectable medications in various doses to placebo for weight loss in persons with Type 2 Diabetes and a BMI above 27. The study drug will be a new Once Weekly Amylin Receptor or Once Weekly Tirzepatide (Mounjaro), alone or in combination versus placebo. Similar agents are currently being used successfully for diabetes and obesity.
Investigational Drug:
Amylin Receptor Agonist, a new once weekly injectable weight loss medication to reduce appetite and body weight alone or in combination with Tirzepatide (Mounjaro), compared with placebo.
To Qualify: Persons age 18 or older diagnosed with Type 2 Diabetes with an HBA1c from 7.0 to 10.5, treated with diet and exercise alone or with a stable dose of meformin, with or without an SGLT2 inhibitor for at least 3 months prior to study.
Goal: To assess investigational medications on weight loss in diabetic persons with obesity with or without risk factors.
Study Categories
Efficacy of New ORAL Weight Loss Medication in Persons without Diabetes
Intro: This study will test a new ORAL, not an injectable, weight loss medication, that is being developed as a daily adjunct therapy to diet and physical activity to improve weight management in adults who have obesity or overweight with weight-related comorbidities.
Investigational Drug: LY3549492 is an oral, non-peptide GLP-1 RA. The study is a 48-week, Phase 2 trial testing the efficacy and safety of 5 dose levels of LY3549492 taken four times a day compared with placebo in the target population.
To Qualify: Persons age 18 to 75 years with a BMI of 27 or more, not diagnosed with diabetes, who have not taken part in a clinical research study for weight loss in the past year, and are not of child bearing potential.